← Eichor
Study identifier: NCT05927454 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Acostill ( RaDiCo Cohort) (RaDiCo Acostill)

Condition: Still Disease · Still's Disease, Adult-Onset · Still Disease, Juvenile Onset  ·  Sponsor: Institut National de la Santé Et de la Recherche Médicale, France

PhaseN/A
Planned participants500
Who can joinAll sexes, N/A to no upper limit
Healthy volunteersNo

About this study

Adult Onset Still Disease (AOSD) and Systemic onset Juvenile Idiopathic Arthritis (SoJIA) are two rare multifactorial diseases associated with systemic inflammation. These two forms AOSD and SoJIA are considered to be two facets of the same syndrome, combining four cardinal symptoms \[hectic fever\> 39 °, arthralgia or arthritis, skin rash, a leukocyte formula with more than 80% of neutrophils\]; lymphadenopathy and splenomegaly may also be found. There is an important biological inflammatory syndrome with elevation of the reactive C protein, of serum ferritin with a dramatic drop in the glycosylated fraction. The incidence of the disease is low, around 0.1/100,000 for adults and 0.6/100,000 for children. Its prevalence is approximately 1 to 3/100,000 and 3/100,000 for children, so there are approximately 500 to 1,500 adults and 450 children affected in France. It is subdivided into pediatric and adult forms according to the age of onset before or after 16 years. The prognosis of the disease is functional and vital. Macrophage activation syndrome (SAM) is frequently associated with either the onset of the disease or the initiation of treatment or concomitantly with viral reactivation. The course over time has mainly been studied in children and is variable: regression, course by flare-ups with term regression and chronic joint development. In adults we can also observe these 3 evolutionary modes. However, differences seem to exist between AOSD and SoJIA. The various clinical…

This description comes directly from the study's public registry record.

Talk to the study team

Sophie Georgin-Lavialle, PHD  ·  0033 156017447  ·  sophie.georgin-lavialle@aphp.fr

Bruno Fautrel, PHD  ·  bruno.fautrel@aphp.fr

Always discuss trial participation with your own doctor first.

Locations (1)

RaDiCo-AcoStillParis, Île-de-France Region, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05927454